We spoke to cartel members, dealers, and users about why North America’s cocaine seems to be getting worse.
Psychedelic compounds found in ‘magic mushrooms’ are increasingly being recognised for their potential to treat health conditions such as depression,...
IntelGenx Corp. (IGX.TO) on Thursday provided an update on its collaboration with its strategic partner, Atai Life Sciences (atai) for the development...
Psychedelic medicines make headlines for indications like PTSD, depression, and anxiety, but they’re being studied for a much broader range of conditions. The...
Ibogaine's ability to "reset" the brain to a pre-addicted state makes it a possible game-changer when it comes to addressing the opioid crisis. The post...
The article Palo Santo Closes $50 Million Psychedelic Investment Fund was originally published on Microdose. Palo Santo Closes $50 Million Psychedelic...
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced...
Clairvoyant Therapeutics, a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased...
The article Breaking News: Compass Pathways to run TWO Phase 3 Trials for Depression was originally published on Microdose. Today, psychedelic medicine...
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety,...